Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2009

01-06-2009

Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility

Authors: T. Y. Kim, D. Vigil, C. J. Der, R. L. Juliano

Published in: Cancer and Metastasis Reviews | Issue 1-2/2009

Login to get access

Abstract

DLC-1 was originally identified as a potential tumor suppressor. One of the key biochemical functions of DLC-1 is to serve as a GTPase activating protein (GAP) for members of the Rho family of GTPases, particularly Rho A-C and Cdc 42. Since these GTPases are critically involved in regulation of the cytoskeleton and cell migration, it seems clear that DLC-1 will also influence these processes. In this review we examine basic aspects of the actin cyoskeleton and how it relates to cell motility. We then delineate the characteristics of DLC-1 and other members of its family, and describe how they may have multiple effects on the regulation of cell polarity, actin organization, and cell migration.
Literature
1.
Yang, J., & Weinberg, R. A. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental Cell, 14(6), 818–829.PubMedCrossRef
2.
3.
Vicente-Manzanares, M., Webb, D. J., & Horwitz, A. R. (2005). Cell migration at a glance. Journal of Cell Science, 118(Pt 21), 4917–4919.PubMedCrossRef
4.
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., et al. (2003). Cell migration: integrating signals from front to back. Science, 302(5651), 1704–1709.PubMedCrossRef
5.
Berrier, A. L., & Yamada, K. M. (2007). Cell-matrix adhesion. Journal of Cellular Physiology, 213(3), 565–573.PubMedCrossRef
6.
Etienne-Manneville, S., & Hall, A. (2002). Rho GTPases in cell biology. Nature, 420(6916), 629–635.PubMedCrossRef
7.
Jaffe, A. B., & Hall, A. (2005). Rho GTPases: biochemistry and biology. Annual Review of Cell and Developmental Biology, 21, 247–269.PubMedCrossRef
8.
Durkin, M. E., Yuan, B. Z., Zhou, X., Zimonjic, D. B., Lowy, D. R., Thorgeirsson, S. S., et al. (2007). DLC-1:a Rho GTPase-activating protein and tumour suppressor. Journal of Cellular and Molecular Medicine, 11(5), 1185–1207.PubMedCrossRef
9.
Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell, 110(6), 673–687.PubMedCrossRef
10.
Larsen, M., Artym, V. V., Green, J. A., & Yamada, K. M. (2006). The matrix reorganized: extracellular matrix remodeling and integrin signaling. Current Opinion in Cell Biology, 18(5), 463–471.PubMedCrossRef
11.
Zaidel-Bar, R., Cohen, M., Addadi, L., & Geiger, B. (2004). Hierarchical assembly of cell-matrix adhesion complexes. Biochemical Society Transactions, 32(Pt3), 416–420.PubMedCrossRef
12.
Del Pozo, M. A., & Schwartz, M. A. (2007). Rac, membrane heterogeneity, caveolin and regulation of growth by integrins. Trends in Cell Biology, 17(5), 246–250.PubMedCrossRef
13.
Juliano, R. L., Reddig, P., Alahari, S., Edin, M., Howe, A., & Aplin, A. (2004). Integrin regulation of cell signalling and motility. Biochemical Society Transactions, 32(Pt3), 443–446.PubMedCrossRef
14.
Moissoglu, K., & Schwartz, M. A. (2006). Integrin signalling in directed cell migration. Biology of the Cell, 98(9), 547–555.PubMedCrossRef
15.
Ridley, A. J., & Hall, A. (2004). Snails, Swiss, and serum: the solution for Rac ‘n’ Rho. Cell, 116(2 Suppl), S23–25, 22 p following S25.PubMedCrossRef
16.
Wennerberg, K., & Der, C. J. (2004). Rho-family GTPases: it’s not only Rac and Rho (and I like it). Journal of Cell Science, 117(Pt 8), 1301–1312.PubMedCrossRef
17.
18.
Nalbant, P., Hodgson, L., Kraynov, V., Toutchkine, A., & Hahn, K. M. (2004). Activation of endogenous Cdc42 visualized in living cells. Science, 305(5690), 1615–1619.PubMedCrossRef
19.
Pertz, O., Hodgson, L., Klemke, R. L., & Hahn, K. M. (2006). Spatiotemporal dynamics of RhoA activity in migrating cells. Nature, 440(7087), 1069–1072.PubMedCrossRef
20.
Weaver, A. M., Young, M. E., Lee, W. L., & Cooper, J. A. (2003). Integration of signals to the Arp2/3 complex. Current Opinion in Cell Biology, 15(1), 23–30.PubMedCrossRef
21.
Bensenor, L. B., Kan, H. M., Wang, N., Wallrabe, H., Davidson, L. A., Cai, Y., et al. (2007). IQGAP1 regulates cell motility by linking growth factor signaling to actin assembly. Journal of Cell Science, 120(Pt 4), 658–669.PubMedCrossRef
22.
Huang, T. Y., DerMardirossian, C., & Bokoch, G. M. (2006). Cofilin phosphatases and regulation of actin dynamics. Current Opinion in Cell Biology, 18(1), 26–31.PubMedCrossRef
23.
Yamaguchi, H., & Condeelis, J. (2007). Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochimica et Biophysica Acta, 1773(5), 642–652.PubMed
24.
Kumar, R., Gururaj, A. E., & Barnes, C. J. (2006). p21-activated kinases in cancer. Nature Reviews Cancer, 6(6), 459–471.PubMedCrossRef
25.
Cai, L., Marshall, T. W., Uetrecht, A. C., Schafer, D. A., & Bear, J. E. (2007). Coronin 1B coordinates Arp2/3 complex and cofilin activities at the leading edge. Cell, 128(5), 915–929.PubMedCrossRef
26.
Krause, M., Dent, E. W., Bear, J. E., Loureiro, J. J., & Gertler, F. B. (2003). Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annual Review of Cell and Developmental Biology, 19, 541–564.PubMedCrossRef
27.
Fukata, Y., Amano, M., & Kaibuchi, K. (2001). Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends in Pharmacological Sciences, 22(1), 32–39.PubMedCrossRef
28.
Pellegrin, S., & Mellor, H. (2007). Actin stress fibres. Journal of Cell Science, 120(Pt 20), 3491–3499.PubMedCrossRef
29.
Watanabe, N., & Higashida, C. (2004). Formins: processive cappers of growing actin filaments. Experimental Cell Research, 301(1), 16–22.PubMedCrossRef
30.
Nayal, A., Webb, D. J., Brown, C. M., Schaefer, E. M., Vicente-Manzanares, M., & Horwitz, A. R. (2006). Paxillin phosphorylation at Ser273 localizes a GIT1-PIX-PAK complex and regulates adhesion and protrusion dynamics. Journal of Cell Biology, 173(4), 587–589.PubMedCrossRef
31.
Nishiya, N., Kiosses, W. B., Han, J., & Ginsberg, M. H. (2005). An alpha4 integrin-paxillin-Arf-GAP complex restricts Rac activation to the leading edge of migrating cells. Nature Cell Biology, 7(4), 343–352.PubMedCrossRef
32.
Dow, L. E., & Humbert, P. O. (2007). Polarity regulators and the control of epithelial architecture, cell migration, and tumorigenesis. International Review of Cytology, 262, 253–302.PubMedCrossRef
33.
Myers, K. R., & Casanova, J. E. (2008). Regulation of actin cytoskeleton dynamics by Arf-family GTPases. Trends in Cell Biology, 18(4), 184–192.PubMedCrossRef
34.
Balasubramanian, N., Scott, D. W., Castle, J. D., Casanova, J. E., & Schwartz, M. A. (2007). Arf6 and microtubules in adhesion-dependent trafficking of lipid rafts. Nature Cell Biology, 9(12), 1381–1391.PubMedCrossRef
35.
Palamidessi, A., Frittoli, E., Garre, M., Faretta, M., Mione, M., Testa, I., et al. (2008). Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell, 134(1), 135–147.PubMedCrossRef
36.
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007). GEFs and GAPs: critical elements in the control of small G proteins. Cell, 129(5), 865–877.PubMedCrossRef
37.
Rossman, K. L., Der, C. J., & Sondek, J. (2005). GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nature Reviews. Molecular Cell Biology, 6(2), 167–180.PubMedCrossRef
38.
Bernards, A., & Settleman, J. (2004). GAP control: regulating the regulators of small GTPases. Trends in Cell Biology, 14(7), 377–385.PubMedCrossRef
39.
Tcherkezian, J., & Lamarche-Vane, N. (2007). Current knowledge of the large RhoGAP family of proteins. Biology of the Cell, 99(2), 67–86.PubMedCrossRef
40.
Kandpal, R. P. (2006). Rho GTPase activating proteins in cancer phenotypes. Current Protein & Peptide Science, 7(4), 355–365.CrossRef
41.
Chang, J. H., Gill, S., Settleman, J., & Parsons, S. J. (1995). c-Src regulates the simultaneous rearrangement of actin cytoskeleton, p190RhoGAP, and p120RasGAP following epidermal growth factor stimulation. Journal of Cell Biology, 130(2), 355–368.PubMedCrossRef
42.
Xue, W., Krasnitz, A., Lucito, R., Sordella, R., Vanaelst, L., Cordon-Cardo, C., et al. (2008). DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes & Development, 22(11), 1439–1444.CrossRef
43.
Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science, 314(5797), 268–274.PubMedCrossRef
44.
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321(5897), 1801–1806.PubMedCrossRef
45.
Yuan, B. Z., Jefferson, A. M., Baldwin, K. T., Thorgeirsson, S. S., Popescu, N. C., & Reynolds, S. H. (2004). DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene, 23(7), 1405–1411.PubMedCrossRef
46.
Yuan, B. Z., Zhou, X., Durkin, M. E., Zimonjic, D. B., Gumundsdottir, K., Eyfjord, J. E., et al. (2003). DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene, 22(3), 445–450.PubMedCrossRef
47.
Zhou, X., Thorgeirsson, S. S., & Popescu, N. C. (2004). Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene, 23(6), 1308–1313.PubMedCrossRef
48.
Healy, K. D., Hodgson, L., Kim, T. Y., Shutes, A., Maddileti, S., Juliano, R. L., et al. (2008). DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Molecular Carcinogenesis, 47(5), 326–337.PubMedCrossRef
49.
Li, H., Fung, K. L., Jin, D. Y., Chung, S. S., Ching, Y. P., Ng, I. O., et al. (2007). Solution structures, dynamics, and lipid-binding of the sterile alpha-motif domain of the deleted in liver cancer 2. Proteins, 67(4), 1154–1166.PubMedCrossRef
50.
51.
Liao, Y. C., Si, L., deVere White, R. W., & Lo, S. H. (2007). The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. Journal of Cell Biology, 176(1), 43–49.PubMedCrossRef
52.
Qian, X., Li, G., Asmussen, H. K., Asnaghi, L., Vass, W. C., Braverman, R., et al. (2007). Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proceedings of the National Academy of Sciences of the United States of America, 104(21), 9012–9017.PubMedCrossRef
53.
Gay, N. J., & Keith, F. J. (1991). Drosophila Toll and IL-1 receptor. Nature, 351(6325), 355–356.PubMedCrossRef
54.
Zhou, X., Zimonjic, D. B., Park, S. W., Yang, X. Y., Durkin, M. E., & Popescu, N. C. (2008). DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. International Journal of Oncology, 32(6), 1285–1291.PubMed
55.
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordon-Cardo, C., et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3(6), 537–549.PubMedCrossRef
56.
Kim, T. Y., Lee, J. W., Kim, H. P., Jong, H. S., Kim, T. Y., Jung, M., et al. (2007). DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 355(1), 72–77.PubMedCrossRef
57.
Syed, V., Mukherjee, K., Lyons-Weiler, J., Lau, K. M., Mashima, T., Tsuruo, T., et al. (2005). Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene, 24(10), 1774–1787.PubMedCrossRef
58.
Wong, C. M., Yam, J. W., Ching, Y. P., Yau, T. O., Leung, T. H., Jin, D. Y., et al. (2005). Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Research, 65(19), 8861–8868.PubMedCrossRef
59.
Euer, N., Schwirzke, M., Evtimova, V., Burtscher, H., Jarsch, M., Tarin, D., et al. (2002). Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Research, 22(2A), 733–740.PubMed
Metadata
Title
Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility
Authors
T. Y. Kim
D. Vigil
C. J. Der
R. L. Juliano
Publication date
01-06-2009
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2009
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9167-2

Other articles of this Issue 1-2/2009

Cancer and Metastasis Reviews 1-2/2009 Go to the issue

OriginalPaper

Tumor stroma derived biomarkers in cancer

NON-THEMATIC REVIEW

The biological role and regulation of versican levels in cancer

OriginalPaper

Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix

NON-THEMATIC REVIEW

The unfolded protein response during prostate cancer development

OriginalPaper

Centrosomes and cancer: how cancer cells divide with too many centrosomes

OriginalPaper

EMT, the cytoskeleton, and cancer cell invasion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits